Tarsus Pharmaceuticals (TARS) COO sells 2,989 shares in planned trade

Rhea-AI Filing Summary

Tarsus Pharmaceuticals Chief Operating Officer Seshadri Neervannan sold 2,989 shares of common stock in an open-market transaction at $66.75 per share on March 20, 2026. The sale was executed automatically under a Rule 10b5-1 trading plan adopted on November 13, 2025. Following the sale, he holds 82,791 shares directly. An additional 475 shares are reported as indirectly held by his daughter, but he disclaims beneficial ownership of those shares.

Insider Trade Summary 10b5-1

Net Seller: 2,989 shares ($199,516)

Net Sell 2 txns

Insider Neervannan Seshadri

Role Chief Operating Officer

Sold 2,989 shs ($200K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,989	$66.75	$200K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 82,791 shares (Direct); Common Stock — 475 shares (Indirect, By daughter)

Footnotes (1)

1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Neervannan Seshadri

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2026		S(1)		2,989	D	$66.75	82,791	D
Common Stock								475	I	By daughter(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

2. This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Tarsus Pharmaceuticals (TARS) report for Seshadri Neervannan?

Tarsus Pharmaceuticals reported that Chief Operating Officer Seshadri Neervannan sold 2,989 shares of common stock. The shares were sold in an open-market transaction at $66.75 per share on March 20, 2026, and were executed under an automatic Rule 10b5-1 trading plan.

How many Tarsus Pharmaceuticals (TARS) shares does the COO hold after the latest Form 4?

After the reported sale, the COO directly holds 82,791 Tarsus Pharmaceuticals shares. The Form 4 also lists 475 shares attributed to his daughter, but he disclaims beneficial ownership of those indirectly reported shares for Section 16 and other legal purposes.

Was the Tarsus Pharmaceuticals (TARS) COO sale under a Rule 10b5-1 trading plan?

Yes, the 2,989-share sale was executed under a Rule 10b5-1 trading plan. The footnote states the automatic sale followed a trading plan adopted by the reporting person on November 13, 2025, indicating the transaction was pre-arranged rather than a discretionary market-timing decision.

What price did the Tarsus Pharmaceuticals (TARS) COO receive for the shares sold?

The COO’s open-market sale occurred at $66.75 per Tarsus Pharmaceuticals share. This transaction involved 2,989 shares of common stock on March 20, 2026, as disclosed in the Form 4, and reflects the per-share sale price for that specific trade.

How are the Tarsus Pharmaceuticals (TARS) shares held by the COO’s daughter treated on the Form 4?

The Form 4 reports 475 shares as indirectly held through the COO’s daughter. A footnote explains these relate to his daughter who shares his household, and he expressly disclaims beneficial ownership of those securities for Section 16 or any other purposes.

Does the Tarsus Pharmaceuticals (TARS) Form 4 show any option exercises by the COO?

No option exercises are reported in this Form 4. The filing only shows an open-market sale of 2,989 common shares and a separate holding entry for 475 indirectly held shares, with no derivative transactions or exercises listed in the derivative summary.